Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection
Open Access
- 4 August 2026
- journal article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0399625
Abstract
Patients with hematologic malignancies (HMs) are particularly vulnerable to coronavirus disease 2019 (COVID-19) because of underlying immune dysfunction and treatment-related immunosuppression. However, proteomic features associated with different clinical trajectories in this population remain insufficiently characterized. We performed serum proteomic analysis in 40 HM patients with COVID-19 and 15 healthy controls. Compared with controls, HM patients showed impaired immune-related responses during the acute phase of COVID-19. Acute-phase proteomic patterns differed across outcome groups; however, because outcome groups were closely intertwined with initial COVID-19 severity, ICU admission, and systemic illness, and because multivariable adjustment was not performed due to the limited sample size, these patterns should be interpreted as severity- and outcome-associated profiles rather than independent trajectory-specific markers. Fatal cases showed evidence of dysregulated immune activation, whereas patients later classified as having long COVID exhibited broader suppression of immune-related pathways. In addition to immune alterations, pathways related to platelet activation and cardiac-related dysfunction were associated with adverse clinical trajectories. Enzyme-linked immunosorbent assay validation supported the association of selected proteins with outcome groups during acute infection. These findings provide a proteomic overview of COVID-19 in HM patients and offer a basis for future mechanistic studies and larger external validation cohorts. IMPORTANCE: Patients with hematologic malignancies are highly vulnerable to severe coronavirus disease 2019 (COVID-19), acute death, and long COVID due to preexisting immune dysfunction. However, the proteomic signatures linked to adverse clinical trajectories remain poorly understood. Our serum proteomic study identifies distinct acute-phase immune profiles associated with different outcomes: broad immune suppression characterizes long COVID, while dysregulated immune activation is associated with fatal cases. Platelet activation and cardiac-related pathways are also linked to poor outcomes. These findings provide key molecular insights for this high-risk population, supporting future biomarker development, risk stratification, and targeted clinical management. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT05683353 .Keywords
Funding Information
- National High Level Hospital Clinical Research Funding (2022CR38)
- Beijing Natural Science Foundation (J230024)
This publication has 32 references indexed in Scilit:
- Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID‐19 vaccine booster shot against Omicron SARS‐CoV‐2 infectionJournal of Medical Virology, 2023
- Sequential multi-omics analysis identifies clinical phenotypes and predictive biomarkers for long COVIDCell Reports Medicine, 2023
- Alterations in platelet proteome signature and impaired platelet integrin αIIbβ3 activation in patients with COVID-19Journal of Thrombosis and Haemostasis, 2023
- Mechanisms of thrombosis and cardiovascular complications in COVID-19Thrombosis Research, 2021
- SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosisJournal of Biological Chemistry, 2021
- Innate and adaptive immune responses against coronavirusBiomedicine & Pharmacotherapy, 2020
- Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19Journal of Allergy and Clinical Immunology, 2020
- Type I IFN immunoprofiling in COVID-19 patientsJournal of Allergy and Clinical Immunology, 2020
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19Cell, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020